Pangenomic enters LOI for distribution deal with Ayla

Executive Summary

• Pangenomic Health Inc. has signed a non-binding Letter of Intent (LOI) with Ayla BioScience Inc. to establish an exclusive distribution partnership and make a strategic equity investment.
• Under the proposed terms, Pangenomic Health will secure exclusive rights to market and distribute Ayla BioScience's "Zeotech" products in Canada for a minimum period of two years.
• Pangenomic Health intends to purchase up to $150,000 worth of shares in Ayla BioScience, payable via a combination of cash and Pangenomic Health shares, subject to final diligence and regulatory approvals.

Key Details

• Parties Involved: Pangenomic Health Inc. (Buyer/Distributor) and Ayla BioScience Inc. (Target/Supplier).
• Transaction Structure: Non-binding Letter of Intent (LOI) leading to an Exclusive Distribution Agreement and a Share Purchase Agreement.
• Distribution Terms:
  • Pangenomic Health gains exclusive rights to market and distribute Zeotech products in Canada.
  • Products are positioned as part of a personalized medicine solution.
  • Minimum duration of the agreement is two years.
• Equity Investment:
  • Maximum purchase price: $150,000.
  • Payment method: Combination of cash and shares of Pangenomic Health.
• Target Company Profile (Ayla BioScience):
  • Jurisdiction: Delaware, USA.
  • Operations: Headquartered in the US with presence in Colombia and Jamaica.
  • Business Model: Vertically integrated biomanufacturing focused on functional food, nutraceuticals, and plant-based bioactive products.
  • Technology: Proprietary solid-state fermentation and dehydration technologies (ZeoDry) for extraction and stabilization of active compounds.
  • Brands: ZeoMycel (functional/medicinal mushrooms) and Zeophytoz (botanical extracts, resins, biocosmetics).
• Regulatory & Closing Conditions:
  • Subject to negotiation of final terms and definitive documentation.
  • Subject to performance of closing conditions.
  • Requires approval by the Canadian Securities Exchange (CSE), if required.
  • Issuance of shares is not anticipated to trigger a change of control under CSE rules.
  • No assurance that the transaction will be completed.

Notable Quotes

• None provided in the source text.